The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

Meningitis remains a significant health problem, affecting 2.5 million people annually and causing death and disability despite the availability of vaccines such as Sanofi’s MenQuadfi that ...